Concepedia

Author

Maxim Kebenko

University Medical Center Hamburg-Eppendorf

Also Known As

M. Kebenko, Maxim Kebenko

42

Publications

790

Citations

13

H-Index

32

Concepts

All Affiliations

University Medical Center Hamburg-EppendorfUniversität HamburgMedizinische Hochschule HannoverUniversity Cancer Center HamburgCharité - Universitätsmedizin Berlin
MK

About

Maxim Kebenko is an author at University Medical Center Hamburg-Eppendorf specializing in medicine, oncology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

6

6

386

2

Cell Biology

2

2

139

3

Immunology

2

2

206

4

Endocrinology

1

1

92

5

Gastroenterology

1

1

26

Maxim Kebenko

×

16

Publications

726

Citations

13

H-Index

YearCitations

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

Maxim Kebenko, Marie-Elisabeth Goebeler, M. Wolf,

OncoImmunology

2018

170

A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating <i>FLT3</i> mutations

Walter Fiedler, Sabine Käyser, Maxim Kebenko,

British Journal of Haematology

2015

104

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

Norbert Vey, Jacques Delaunay, Giovanni Martinelli,

Oncotarget

2016

94

T3-mediated expression of PGC-1α via a far upstream located thyroid hormone response element

Anne Wulf, Angelika Harneit, Meike Kröger,

Molecular and Cellular Endocrinology

2008

92

ErbB2 signaling activates the Hedgehog pathway via PI3K–Akt in human esophageal adenocarcinoma: Identification of novel targets for concerted therapy concepts

Maxim Kebenko, Astrid Drenckhan, Stephanie J. Gros,

Cellular Signalling

2014

47

A phase I study of  EpCAM/CD3-bispecific antibody (MT110) in patients with advanced solid tumors.

Walter Fiedler, M. Wolf, Maxim Kebenko,

Journal of Clinical Oncology

2012

36

Combined inhibition of GLI and FLT3 signaling leads to effective anti-leukemic effects in human acute myeloid leukemia

Emily-Marie Latuske, Hauke Stamm, Marianne Klokow,

Oncotarget

2017

33

Favorable Outcome in a Large Cohort of Prospectively Treated Adult Patients with T-Lymphoblastic Lymphoma (T-LBL) Despite Slowly Evolving Complete Remission Assessed By Conventional Radiography

Nicola Gökbuget, Andrea Wolf, Matthias Stelljes,

Blood

2014

27

Phase I study of AMG 211/MEDI-565 administered as continuous intravenous infusion (cIV) for relapsed/refractory gastrointestinal (GI) adenocarcinoma

Kirsten L. Moek, Walter Fiedler, Jobst C. von Einem,

Annals of Oncology

2018

26

Treatment of Angiosarcoma with Pazopanib and Paclitaxel: Results of the EVA (Evaluation of Votrient® in Angiosarcoma) Phase II Trial of the German Interdisciplinary Sarcoma Group (GISG-06)

Daniel Pink, Dimosthenis Andreou, Sebastian Bauer,

Cancers

2021

23

Page 1